Tag : BRUTON’S TYROSINE KINASE INHIBITORS
The phase 3 HERCULES trial demonstrates that tolebrutinib reduces disability progression in non-relapsing secondary progressive multiple sclerosis (nrSPMS) by 31%, offering hope for this underserved population.
